Journal of child and adolescent psychopharmacology最新文献

{"title":"Results from a Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Trial of Lovastatin or Minocycline in Fragile X Syndrome.","authors":"Walker S McKinney, Lauren M Schmitt, Lisa A De Stefano, Lauren Ethridge, Jordan E Norris, Paul S Horn, Shelby Dauterman, Hilary Rosselot, Ernest V Pedapati, Debra L Reisinger, Kelli C Dominick, Rebecca C Shaffer, Danielle Chin, Nicole R Friedman, Michael Hong, John A Sweeney, Craig Erickson","doi":"10.1089/cap.2024.0103","DOIUrl":"10.1089/cap.2024.0103","url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Treatment studies in <i>FMR1</i> knockout rodent models have found that minocycline and lovastatin each improve synaptic, neurological, and behavioral functioning, and open-label chronic dosing studies in human patients with fragile X syndrome (FXS) have demonstrated modest clinical improvements. Findings from blinded studies are mixed, and there is a limited understanding of electrophysiological target engagement that would facilitate cross-species translational studies. Smaller-scale, acute (e.g., single-dose) drug studies may speed treatment identification by detecting subtle electrophysiological and behavioral changes. <b><i>Materials and Methods:</i></b> Twenty-nine participants with FXS (31% female) ages 15-45 years completed a randomized, double-blind, crossover study in which they received a single oral dose of 40 mg of lovastatin, 270 mg of minocycline, or placebo, with a 2-week washout period between dosing visits. Participants completed a comprehensive neuropsychological battery and three EEG paradigms (resting state; auditory chirp; auditory habituation) before and 4 hours after dosing. <b><i>Results:</i></b> No serious adverse events were reported, and both drugs were well-tolerated. Compared with placebo, there were no overall treatment effects for any outcomes, including EEG, but several modest drug responses varied as a function of sex and age. Lovastatin treatment was associated with improved spatial awareness in older participants and females compared with minocycline and placebo. <b><i>Discussion:</i></b> We show that single-dose drug studies are highly feasible in FXS and that patients with FXS can complete a range of EEG and behavioral tasks, many of which have been shown to be reliable and may therefore be sensitive to subtle drug target engagement. <b><i>Conclusions:</i></b> Acute single doses of lovastatin or minocycline did not lead to changes in electrophysiological or performance-based measures. This may be due to the limited effects of these drugs in human patients or limited acute effects relative to chronic dosing. However, the study design was further validated for use in neurodevelopmental populations.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"211-221"},"PeriodicalIF":1.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From the Editor-in-Chief's Desk: Special Issue on the Psychopharmacology of Neurodevelopmental Disorders.","authors":"Paul E Croarkin","doi":"10.1089/cap.2025.0030","DOIUrl":"10.1089/cap.2025.0030","url":null,"abstract":"","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"173-174"},"PeriodicalIF":1.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Agitation Management in a 5-Year-Old Boy with X Chromosome-Linked Monoamine Oxidase-A and Monoamine Oxidase-B Deficiency.","authors":"Can Beser, Genevieve Davis, Megan O'Connell, Adam Ali","doi":"10.1089/cap.2024.0074","DOIUrl":"10.1089/cap.2024.0074","url":null,"abstract":"","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"257-258"},"PeriodicalIF":1.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Frequency Utilization of the Outpatient Messaging System in a Specialized Outpatient Catatonia Clinic for Individuals with Autism Spectrum Disorder.","authors":"Joshua R Smith, Donald G Sengstack, Allison B McCoy, Seri Lim, Sarah Marler, Zachary J Williams, Nausheen Hossain, James Luccarelli","doi":"10.1089/cap.2025.0034","DOIUrl":"https://doi.org/10.1089/cap.2025.0034","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> Catatonia is a highly morbid psychomotor disorder that impacts autistic adults and children. There is very little literature that describes outpatient catatonia management practices, none of which discusses the use of the electronic health record (EHR). Thus, we conducted this study to analyze patient messages in a specialized catatonia clinic. <b><i>Methods:</i></b> We conducted a retrospective analysis of messaging practices in the EHR for patients in a specialized clinic with autism and catatonia from July 1, 2021, to May 31, 2024. Catatonic symptom severity was recorded via the Bush Francis Catatonia Rating Scale (BFCRS), Kanner Catatonia Severity Scale (KCS), and Kanner Catatonia Examination (KCE). We conducted Spearman and Pearson correlation coefficients to determine whether a relationship exists between the frequency of patient messages, catatonic symptoms, and length of follow-up. <b><i>Results:</i></b> A total of 12,972 messages were sent to the health system or received by the patient or their family. Of those, 6375 (49.1%) messages were sent from the family to the health system. Relationships between message frequency to the health system and all baseline catatonia severity scores (BFCRS, KCS, KCE) were not statistically significant, although message frequency was strongly associated with length of follow-up (<i>r</i> = 0.65, <i>p</i> < 0.001). A total of 5555 (42.8%) messages were sent directly to or received from providers in the catatonia specialty clinic. The rate of messages to providers in the catatonia clinic was 2.9 messages/day. <b><i>Conclusion:</i></b> The frequency of patient messaging was high in this catatonia specialty clinic. Health systems should consider this possibility when planning for similar service lines.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Food and Drug Administration Clearance of Transcranial Magnetic Stimulation for Adolescent Depression in the Absence of Data Supporting Efficacy.","authors":"Kristina T Kumpf, Marcus Hughes, Michael H Bloch","doi":"10.1089/cap.2024.0142","DOIUrl":"https://doi.org/10.1089/cap.2024.0142","url":null,"abstract":"","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>SPTAN1</i>-Results of a Caregiver Survey.","authors":"Michelle Wilson, Francis Wong","doi":"10.1089/cap.2024.0100","DOIUrl":"https://doi.org/10.1089/cap.2024.0100","url":null,"abstract":"<p><p><b><i>Background:</i></b> <i>SPTAN1</i> variants are thought to affect the scaffolding that protects the axonal segment of neurons as well as neuronal synapses. The <i>SPTAN1</i> gene is located in the 9q34.11 genomic region and encodes the cytoskeletal protein alpha II spectrin. Epilepsy, encephalopathy, and motor neuropathy are most commonly associated with <i>SPTAN1</i> variants. <b><i>Methods:</i></b> An informed consent and questionnaire were developed in order to gather information from caregivers regarding their family members' <i>SPTAN1</i> variant. Survey results are summarized descriptively, in order of frequency. <b><i>Results:</i></b> The results of a questionnaire filled out by the caregivers of loved ones who have a <i>SPTAN1</i> mutation are summarized for 25 individuals, 14 males and 11 females, who have the <i>SPTAN1</i> mutation. <b><i>Conclusions:</i></b> The results of this survey mirror those reported by other authors and include epilepsy, intellectual and motor delays, encephalopathy, and motor neuropathy. Additional effects of the <i>SPTAN1</i> mutation reported here include absent or difficult speech, happy personality, decline in cognitive and motor skills with age, vision and hearing abnormalities, organ and skeletal effects, autoimmune diseases, and weakened immune systems.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Collaborating with Applied Behavior Analysis Teams to Optimize Telehealth Pharmacologic Management of Catatonia in Nonverbal Youth with Autism Spectrum Disorder.","authors":"Sally Chu, H Yavuz Ince","doi":"10.1089/cap.2025.0021","DOIUrl":"https://doi.org/10.1089/cap.2025.0021","url":null,"abstract":"","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Concomitant Psychostimulants Mitigate Second-Generation Antipsychotics-Associated Weight Gain? An Observational Study Based on Electronic Medical Records Data.","authors":"Ning Lyu, Paul J Rowan, Tyler J Varisco, Susan Abughosh, Ying Lin, Hua Chen","doi":"10.1089/cap.2024.0135","DOIUrl":"https://doi.org/10.1089/cap.2024.0135","url":null,"abstract":"<p><p><b><i>Objective:</i></b> Weight loss is a well-documented adverse effect of psychostimulants. Given their frequent coprescription with second-generation antipsychotics (SGA) in pediatric patients, this study aims to examine whether concomitant use of psychostimulants mitigates SGA-associated weight gain in children and adolescents. <b><i>Method:</i></b> This study utilized the IQVIA Ambulatory electronic medical record-U.S. database (2016-2021) to identify patients aged 6-17 years who initiated an SGA. Those who started psychostimulants within 7 days of SGA initiation and maintained ≥90 days of use were classified as concomitant users, while those who initiated psychostimulants later with ≥90 days of overlap were add-on users. Patients never prescribed psychostimulants were SGA-only users. After adjusting for the baseline covariates using propensity scores, 6- and 12-month body mass index (BMI) <i>z</i>-score trends following psychostimulant initiation were compared between (1) concomitant and SGA-only users and (2) add-on and SGA-only users, using a linear mixed-effects regression model. <b><i>Results:</i></b> The results of linear mixed effect regression models indicate that concomitant users experienced a 0.0143 less monthly BMI <i>z</i>-score increase (<i>p</i> = 0.0063) compared with the SGA-only users over the 6 months following psychostimulant initiation. Similarly, add-on users had a significantly lower rate of weight gain compared with SGA-only users (<i>β</i> = -0.0463, <i>p</i> < 0.0001). When the follow-up period was extended to 12 months, the sensitivity analyses for both concomitant and add-on users were consistent with their primary analyses. <b><i>Conclusions:</i></b> Concomitant and add-on psychostimulants appear to mitigate SGA-associated weight gain in children and adolescents. Further investigation is needed to understand their effectiveness and safety relative to other interventions for antipsychotic-associated weight gain.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot Trial on the Effects of Propranolol on Gastrointestinal Symptoms in Autism Spectrum Disorder and Heart Rate Variability as a Treatment Response Biomarker.","authors":"Bradley J Ferguson, Kristen Dovgan, Mackenzie Hoffman, Molly Hogg, Cayce Rose, David Q Beversdorf","doi":"10.1089/cap.2024.0002","DOIUrl":"https://doi.org/10.1089/cap.2024.0002","url":null,"abstract":"<p><p><b><i>Background:</i></b> Many individuals with autism spectrum disorder (ASD) experience gastrointestinal (GI) symptoms, which can impact social interactions, exacerbate social communication deficits, and decrease the quality of life. GI symptoms have been shown to be correlated with the autonomic nervous system and endocrine response to stress in some people with ASD. Furthermore, propranolol, a central and peripheral beta-adrenergic antagonist that inhibits the stress response, has been shown to provide GI relief for some individuals with ASD, but not others. This pilot study examined whether baseline (i.e., resting) heart rate variability (HRV), a biomarker that is sensitive to the stress response, predicted the response to propranolol in decreasing GI symptoms. <b><i>Methods:</i></b> In this pilot study, a sample of 37 individuals with ASD participated in a 12-week open-label trial of propranolol. The Gastrointestinal Severity Index and HRV were collected at baseline (i.e., prior to taking propranolol) and again at the end of the 12-week trial period. <b><i>Results:</i></b> Higher HRV was associated with the greatest reduction in GI symptoms, with a strong effect size, but only for adolescents and young adults (15-24 years old). Baseline HRV and GI change scores were not significantly correlated for younger children (7-14 years old). <b><i>Conclusions:</i></b> The results from this open-label pilot trial suggest that autistic adolescents and young adults with higher baseline HRV, indicating greater parasympathetic tone, may respond better to propranolol and show the greatest reduction in GI symptoms. The data from this pilot should be interpreted with caution until larger, randomized, double-blinded, placebo-controlled trials of propranolol for GI symptoms in ASD are completed.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor.","authors":"Isabella Sutherland, Ming-Fen Ho, Paul E Croarkin","doi":"10.1089/cap.2024.0082","DOIUrl":"10.1089/cap.2024.0082","url":null,"abstract":"<p><p>Interest in psychedelic therapies for adults is rapidly growing, with substances like 3,4-methylenedioxymethamphetamine for posttraumatic stress disorder, psilocybin for treatment-resistant depression, and lysergic acid diethylamide for generalized anxiety disorder showing promise. However, research on these therapies in children and adolescents is limited, with no recent trials. Despite this lack of scientific exploration, adolescents may still experiment with these substances for both recreational and therapeutic purposes as accessibility continues to increase. This raises significant concerns, as adolescents are a vulnerable population requiring heightened caution and safety measures. Therefore, we advocate for structured, safe, and well-controlled exploration of psychedelic therapies in adolescents.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":"118-125"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}